Ebglyss (lebrikizumab)
Research Synopsis
- - Recent research on Ebglyss (lebrikizumab) indicates its potential as a treatment for severe asthma, particularly in patients with high interleukin-13 (IL-13) activity and serum periostin levels.
- - In a clinical trial, lebrikizumab demonstrated significant improvements in lung function among patients with poorly controlled asthma, especially those expressing high levels of periostin.
- - Lebrikizumab aims to block IL-13 signaling, a critical pathway involved in asthma inflammation, which may lead to greater efficacy compared to traditional treatments targeting broader inflammatory pathways.
- - The drug's safety profile shows some concerns, as patients have reported musculoskeletal side effects, highlighting the need for careful patient monitoring during treatment.
- - A dose-ranging study noted that while lebrikizumab did not significantly enhance lung function in all patients, it effectively reduced the risk of treatment failure, suggesting potential benefits for asthma control.
- - Systematic reviews of systemic treatments for atopic dermatitis also noted variability in treatment response, suggesting that lebrikizumab's targeted approach may provide better outcomes in certain cohorts.
- - The structural analysis of lebrikizumab has revealed its binding capability to IL-13, indicating a well-defined mechanism that may enhance treatment efficacy relative to existing therapies.
- - Ongoing Phase III trials are critical to determining which specific asthma phenotypes respond best to lebrikizumab, aligning with the emerging trend of personalized medicine in asthma treatment.
- - As asthma is a complex disorder with various phenotypes, successful treatment with lebrikizumab may rely on identifying biomarkers that predict patient responses, reaffirming the shift towards targeted therapy.
- - Overall, lebrikizumab appears to be a promising candidate in the biologics market, aiming to provide more effective treatment options for patients with severe asthma who have not responded well to conventional therapies.
Ebglyss (lebrikizumab)
Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials.
London, UK
2 hours ago
1 Received
- Atopic dermatitis (AD) is a skin condition that causes inflammation and can be treated in different ways, but it's not always clear which treatments work best.
- Researchers looked at many studies to compare the benefits and risks of different treatments for AD.
- They found that some treatments, like high-dose upadacitinib, were very effective but also had more side effects, while others like dupilumab were safer but less powerful.
$100 - $150
Hourly Rate
Lebrikizumab treatment in adults with asthma.
London, UK
2 hours ago
1 Received
- Many asthma patients still struggle to control their symptoms even when using inhaled glucocorticoids, potentially due to differences in interleukin-13 expression affecting treatment response.
- A clinical trial tested lebrikizumab, an antibody targeting interleukin-13, on 219 adults with poorly controlled asthma, measuring changes in lung function (FEV1) over a 12-week period.
- Results showed that patients with high levels of periostin benefited most from lebrikizumab, experiencing significant improvements in lung function compared to placebo, although some experienced more musculoskeletal side effects.
$100 - $150
Hourly Rate
Attacks on asthma.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Lebrikizumab treatment in adults with asthma.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Lebrikizumab treatment in adults with asthma.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Lebrikizumab treatment in adults with asthma.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Pulmonary hypertension as a risk factor for graft dysfunction, ultrasound-guided subclavian vein cannulation, and lebrikizumab for adult asthma.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Childhood nephrotic syndrome--current and future therapies.
London, UK
2 hours ago
1 Received
- The introduction of corticosteroids over 50 years ago greatly improved outcomes for children with nephrotic syndrome, but many patients still don't respond to this treatment and face the risk of end-stage renal disease.
- New therapies are needed for those who are steroid-resistant, with historical approaches focusing mainly on alternative immunosuppressive drugs like ciclosporin and tacrolimus.
- Recent findings suggest that the disease stems from dysfunction in podocytes rather than just immune responses, leading to a reevaluation of treatment strategies and highlighting potential new pathways for future therapies.
$100 - $150
Hourly Rate
Update in asthma 2011.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Lebrikizumab in the personalized management of asthma.
London, UK
2 hours ago
1 Received
- * IL-13 plays a significant role in asthma inflammation, and blocking it with lebrikizumab has shown some promise, particularly in improving lung function in patients with high serum periostin levels.
- * Current research, including ongoing Phase III trials, aims to further evaluate the efficacy and safety of lebrikizumab in treating poorly controlled asthma and to identify which patients may benefit the most from this therapy.
$100 - $150
Hourly Rate
The potential of biologics for the treatment of asthma.
London, UK
2 hours ago
1 Received
- The established use of omalizumab (Xolair) shows the potential of biologics as add-on treatments for asthma that isn't well-controlled.
- As more biologics targeting interleukin-5 and interleukin-13 show promise, understanding different asthma subtypes will be crucial for personalized treatment strategies.
$100 - $150
Hourly Rate
Asthma phenotypes and endotypes.
London, UK
2 hours ago
1 Received
- Asthma is not a single disease but a complex disorder with various types and responses to treatment, highlighting the need for personalized medicine.
- Recent research has led to the identification of different asthma phenotypes and endotypes, prompting clinical trials to target specific asthma subgroups, like the trial using lebrikizumab.
- Severe asthma presents challenges as patients struggle with persistent symptoms and require high medication dosages; new findings suggest that various immune responses, including non-Th2 pathways, play a significant role in its severity.
$100 - $150
Hourly Rate
Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab.
London, UK
2 hours ago
1 Received
- IL-13 is a crucial cytokine involved in allergic diseases like asthma, triggering inflammation through its receptor complex with IL-13Rα1 and IL-4Rα.
- Antibodies against IL-13 can diminish its inflammatory impact; specifically, lebrikizumab is a monoclonal antibody that has shown promise in treating uncontrolled asthma in clinical trials.
- This study reveals the molecular structure of IL-13 bound to lebrikizumab and demonstrates that lebrikizumab effectively blocks IL-13 signaling by preventing its interaction with the IL-4Rα receptor.
$100 - $150
Hourly Rate
Which are the antibodies to watch in 2013?
London, UK
2 hours ago
1 Received
- The annual review of therapeutic monoclonal antibodies (mAbs) highlights about 350 mAbs in various stages of clinical development, focusing on those in active Phase 2/3 or Phase 3 studies.
- As of early 2013, 28 single mAbs and one mAb combination are on the "Antibodies to watch" list, targeting conditions like cancers, Alzheimer's disease, and inflammatory disorders.
- The combination of actoxumab and bezlotoxumab is specifically being tested in Phase 3 studies for treating Clostridium difficile infections.
$100 - $150
Hourly Rate
Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines.
London, UK
2 hours ago
1 Received
- * This study introduces a method to create bispecific antibodies using the human IgG4 isotype, specifically targeting cytokines IL-4 and IL-13 linked to type 2 inflammation.
- * The researchers successfully produced IgG4 bispecific antibodies in large quantities, demonstrating similar efficiency, quality, and pharmacokinetic properties as IgG1, opening up new options for therapeutic development.
$100 - $150
Hourly Rate
Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids.
London, UK
2 hours ago
1 Received
- - The study evaluated lebrikizumab, an anti-IL-13 treatment, in patients with asthma who were not using inhaled corticosteroids, aiming to see if it could improve lung function and reduce treatment failures.
- - 212 patients received different doses of lebrikizumab or a placebo, with the primary outcome being the change in lung function (FEV1) after 12 weeks; results showed no significant improvement compared to placebo.
- - Although lebrikizumab did not significantly enhance lung function, it effectively reduced the risk of treatment failure, indicating potential benefits in managing asthma control.
$100 - $150
Hourly Rate
Role of interleukin-13 in asthma.
London, UK
2 hours ago
1 Received
- Interleukin-13 (IL-13) is a key TH2 cytokine involved in asthma development, affecting various bodily processes like goblet cell differentiation and B cell antibody production.
- Research has identified several biomarkers associated with IL-13 activity, such as elevated blood eosinophils and specific proteins, which can predict treatment responses to inhaled corticosteroids and help in selecting patients for anti-IL-13 therapies.
- A clinical trial on lebrikizumab, an anti-IL-13 antibody, showed notable improvements in lung function for patients with high serum periostin levels, suggesting that targeting IL-13 could be beneficial for those with severe asthma.
$100 - $150
Hourly Rate
Anti-IL-13 in inflammatory bowel disease: from the bench to the bedside.
London, UK
2 hours ago
1 Received
- * It has a variety of effects on health, influencing conditions like asthma and cancer, which makes it a target for potential treatments.
- * Current research focuses on developing drugs that inhibit IL-13, suggesting they could be effective therapeutic options for managing IBD and similar conditions in the future.
$100 - $150
Hourly Rate
Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthma.
London, UK
2 hours ago
1 Received
- - Human asthma is not a one-size-fits-all condition; it varies widely in airway inflammation, which has been studied through genomic approaches revealing different gene expression patterns related to type 2 cytokines and eosinophils.
- - New biomarkers like serum periostin, fractional exhaled nitric oxide, and blood eosinophil counts have been identified, helping to evaluate eosinophilic inflammation without invasive procedures and showing promise in clinical settings for biologic therapies targeting specific interleukins and immunoglobulin E.
- - Ongoing research aims to find effective cutoff points for these biomarkers, ensuring that new asthma treatments are tailored to the right patients based on their specific type of airway inflammation.
$100 - $150
Hourly Rate
Monoclonal antibodies for the treatment of refractory asthma.
London, UK
2 hours ago
1 Received
- Severe asthma affects a small number of patients and is marked by ongoing airflow obstruction and inflammation, prompting research into targeted therapies using monoclonal antibodies.
- Recent developments highlight the importance of recognizing different severe asthma subtypes (endotypes) and using specific biomarkers to tailor biologic treatments for patients not responding to standard medications.
- Understanding the mechanisms of airway inflammation and identifying the right biomarkers are essential for effectively administering biologics that target the underlying issues in severe refractory asthma.
$100 - $150
Hourly Rate